Because PD-1 is a clinically predominant immunotherapy target, we also administered anti‐PD-1 to MC38‐bearing WT and Nrf2flox/flox LysMCre mice on day 8 after tumor implantation. This evidence concerns the gene PDCD1 and neoplasm.